Earnings summaries and quarterly performance for vTv Therapeutics.
Executive leadership at vTv Therapeutics.
Board of directors at vTv Therapeutics.
Research analysts covering vTv Therapeutics.
Recent press releases and 8-K filings for VTVT.
vTv Therapeutics Inc. announces expanded licensing agreement for HPP737
VTVT
New Projects/Investments
Revenue Acceleration/Inflection
- On January 30, 2026, vTv Therapeutics Inc.'s subsidiary, vTv Therapeutics LLC, entered into a Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd..
- This amendment expands Newsoara's rights to vTv LLC's PDE4 inhibitor, HPP737, to include all countries of the world.
- The agreement includes an upfront payment of $20 million from Newsoara, along with eligibility for vTv LLC to receive up to $50 million in development milestones, $65 million in sales-related milestones, and mid-single-digit royalties on sales volumes.
4 days ago
vTv Therapeutics Reports Q3 2025 Financial Results and Corporate Updates
VTVT
Earnings
New Projects/Investments
Debt Issuance
- vTv Therapeutics reported a net loss of $8.7 million or $1.08 per basic share for the third quarter ended September 30, 2025, with its cash position at $98.5 million as of that date.
- The company completed an $80 million private placement in September 2025 to strengthen its balance sheet and fund the ongoing Phase 3 CATT1 trial.
- The first patient was randomized in the Phase 3 CATT1 trial for cadisegliatin in August 2025, and topline data is expected in the second half of 2026.
- A new U.S. patent for cadisegliatin, covering crystalline salts and co-crystals, was allowed in August 2025, extending exclusivity to 2041.
Nov 6, 2025, 9:26 PM
vTv Therapeutics Reports Q3 2025 Financial Results and Key Program Updates
VTVT
Earnings
New Projects/Investments
- vTv Therapeutics strengthened its balance sheet with an $80 million private placement in September 2025, intended to fund the ongoing CATT1 Phase 3 trial and cadisegliatin program.
- The company reported a cash position of $98.5 million as of September 30, 2025.
- The first patient was randomized in the Phase 3 CATT1 trial for cadisegliatin in August 2025, with topline data expected in the second half of 2026.
- A new U.S. patent for crystalline forms of cadisegliatin was allowed in August 2025, extending exclusivity out to 2041.
- For the third quarter ended September 30, 2025, the company reported a net loss of $8.7 million, or $1.08 per basic share.
Nov 6, 2025, 9:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more